Q-omics provides the consensus-scored RAB39B profile across patient tissues and cancer cell-line models. RAB39B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAB39B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RAB39B RNA expression shows 18,583 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where RAB39B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB39B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB39B survival associations across molecular data types. RAB39B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB39B RNA expression–survival associations across cancer types. High RAB39B expression shows unfavorable associations in UCEC, but favorable associations in HNSC, LUAD, PAAD, SKCM and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAB39B RNA expression.
This table summarizes RAB39B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB39B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB39B shows lower tumor expression in COAD, KIRP, KIRC, KICH and LUAD and higher tumor expression in BRCA. The COAD box plot shows higher RAB39B RNA expression in normal versus tumor tissue (log2 FC = −0.714, t-test p < 0.001).
This table shows molecular features associated with RAB39B in patient tissues and cancer cell lines. In patient samples, RAB39B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB39B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
